These sports innovation companies have joined Pokatok. Photo via Getty Images

A Houston-based organization focused on advancing sports tech startups has named its latest cohort.

Pokatok Labs announced the addition of six companies to its portfolio as the program — focused on seed and series A startups across health tech, gaming, fan experience, and more — kicks off. Lasting nine weeks and held twice a year, Pokatok's inaugural cohort was announced in May. Participating companies receive access to a network of organizations, advisors, investors, and subject matter experts within sports tech.

"We are pumped to launch our second cohort of all-star companies. If it's possible, this collection of startups may be even more outstanding than the last group," says Lawson Gow, Pokatok's co-founder. "We are eager to immerse them into the Texas market and to otherwise support their growth in any way that we can."

Gow, founder of The Cannon, launched the program with Chris Buckner, founder of Mainline, and Alex Gras, former chief commercial officer of The Cannon. (Note: Lawson Gow is the son of David Gow, the CEO of InnovationMap's parent company, Gow Media.)

The fall 2022 cohort for Pokatok includes:

Adapt Brands

Image via adaptbrands.com

California-based Adapt Brands is a superfood company that's creating Hemp-infused products as natural alternatives to synthetic beverages, supplements, and opioids. The company is founded by CEO Richard Harrington.

AGOGIE

Image via agogie.com

AGOGIE — based in St. Louis, Missouri, and founded by CEO Aaron Mottern — designs apparel with resistance bands built inside, creating a new category of apparel that burns calories and fat, activates and strengthens muscle, and is suitable for all day wear.

Fabric

Photo via fabric.space

Los Angeles-based Fabric brings fandom to the metaverse with its a geospatial web platform that enables sports teams to create and launch a Space, an interactive and social 3D jumbotron.

Ongo

Image via ongo.com

Ongo, headquartered in San Francisco, is a subscription-based software company designing solutions for users to approach health and wellness.

Recut

Image via Unsplash

New York-based Recut provides tools for users to personalized video content at scale.

Tallysight

Image via tallysight.com

Tallysight, founded in San Diego by CEO Matt Peterson, is an all-in-one creator monetization platform for individuals and businesses in digital sports media and betting.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.